Publications

British journal of clinical pharmacology

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.

01-02-2013

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection.

15-01-2013

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.

15-01-2013

Cancer chemotherapy and pharmacology

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.

01-01-2013

Therapeutic advances in medical oncology

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients.

01-01-2013

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel.

01-01-2013

Pharmaceutical research

Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab.

01-12-2012

Cancer chemotherapy and pharmacology

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.

01-12-2012

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion.

01-12-2012

BMJ (Clinical research ed.)

Commentary: Substandard medicines are the priority for neglected tropical diseases.

14-11-2012

Molecular pharmaceutics

Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.

05-11-2012

Cancer chemotherapy and pharmacology

Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.

01-11-2012

Bioanalysis

Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.

01-11-2012

Molecular pharmaceutics

Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice.

04-09-2012

The AAPS journal

Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses.

01-09-2012

Cytometry. Part A : the journal of the International Society for Analytical Cytology

Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells.

01-08-2012

Investigational new drugs

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).

01-08-2012

British journal of clinical pharmacology

Model-based treatment optimization of a novel VEGFR inhibitor.

01-08-2012

Investigational new drugs

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.

01-08-2012

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection.

15-07-2012

Drug metabolism and disposition: the biological fate of chemicals

Metabolite profiling of bendamustine in urine of cancer patients after administration of [14C]bendamustine.

01-07-2012

The oncologist

Concise drug review: pazopanib and axitinib.

27-06-2012

Breast cancer research and treatment

Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen.

01-06-2012

Cancer chemotherapy and pharmacology

Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study.

01-06-2012

Journal of palliative care

Severe cannabinoid intoxication in a patient with non-small-cell lung cancer.

16-05-2012

British journal of cancer

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours.

08-05-2012

Cancer

Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.

01-05-2012

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine.

15-04-2012

The oncologist

Lapatinib for advanced or metastatic breast cancer.

06-04-2012

The Journal of pharmacology and experimental therapeutics

P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.

01-04-2012

Investigational new drugs

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.

01-04-2012

Journal of clinical pharmacology

From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies.

01-03-2012

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices.

01-03-2012

Journal of clinical pharmacology

Model-based evaluation of similarity in pharmacokinetics of two formulations of the blood-derived plasma product c1 esterase inhibitor.

01-02-2012

Drug metabolism and disposition: the biological fate of chemicals

Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.

01-02-2012

Cancer chemotherapy and pharmacology

Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.

01-01-2012

International journal of cancer

Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.

01-01-2012

Journal of clinical laboratory analysis

Search for breast cancer biomarkers in fractionated serum samples by protein profiling with SELDI-TOF MS.

01-01-2012

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates.

15-12-2011

Bioanalysis

Bioanalytical aspects of clinical mass balance studies in oncology.

01-12-2011

Cancer treatment reviews

Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials.

01-12-2011

Journal of cancer research and clinical oncology

Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer.

01-12-2011

International journal of pharmaceutics

Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).

28-11-2011

Lung cancer (Amsterdam, Netherlands)

Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.

01-11-2011

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry.

15-10-2011

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial.

10-10-2011

Investigational new drugs

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice.

01-10-2011

Journal of analytical toxicology

Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.

01-10-2011

International journal of pharmaceutics

Optimizing the therapeutic index of liposomal glucocorticoids in experimental arthritis.

20-09-2011

Clinical cancer research : an official journal of the American Association for Cancer Research

Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.

15-09-2011

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.

Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection.

Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients.

Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel.

Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab.

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.

Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion.

Commentary: Substandard medicines are the priority for neglected tropical diseases.

Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.

Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.

Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.

Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice.

Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses.

Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells.

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).

Model-based treatment optimization of a novel VEGFR inhibitor.

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.

Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection.

Metabolite profiling of bendamustine in urine of cancer patients after administration of [14C]bendamustine.

Concise drug review: pazopanib and axitinib.

Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen.

Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study.

Severe cannabinoid intoxication in a patient with non-small-cell lung cancer.

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours.

Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.

Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine.

Lapatinib for advanced or metastatic breast cancer.

P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.

From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies.

Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices.

Model-based evaluation of similarity in pharmacokinetics of two formulations of the blood-derived plasma product c1 esterase inhibitor.

Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.

Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.

Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.

Search for breast cancer biomarkers in fractionated serum samples by protein profiling with SELDI-TOF MS.

High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates.

Bioanalytical aspects of clinical mass balance studies in oncology.

Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials.

Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer.

Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).

Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.

A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry.

Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial.

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice.

Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.

Optimizing the therapeutic index of liposomal glucocorticoids in experimental arthritis.

Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.

This site uses cookies